San Rocco Therapeutics, LLC (“SRT”) Pushes Clinical Trial for a Curative Treatment for Beta-Thalassemia and Sickle Cell Disease

TAMPA, Fla.–(BUSINESS WIRE)–Using the SRT vector and myelosuppressive preparation therapy, Memorial Sloan Kettering (“MSK”) reported encouraging results in Nature Medicine, [Boulad, F., Maggio, A., Wang, X. et al. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial. Nat Med 28, 63–70 (2022). https://doi.org/10.1038/s41591-021-01554-9]. The clinical trial using the SRT vector demonstrates that two out of three patients had a reduction in transfusions by 43% for almost a decade.

View the rest of the article here

View the PDF